secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0000950170-22-015505
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta posts Q3 loss of $31.7M; sues Pfizer for Paxlovid patent infringement
----------------------------------------------------------------------------

- Net loss of $31.7M ($1.53 diluted loss per share) vs $24.0M loss ($1.19) in prior year; revenue $19.5M from AbbVie royalties, down from $21.6M.
- Cash, equivalents and marketable securities $292.7M; expects sufficient for two years.
- Filed patent infringement suit against Pfizer over Paxlovid; seeks damages, not injunction; patent awarded June 2022.
- EDP-235 Phase 1 data positive; Phase 2 study planned Q4 2022; RSV programs include new Phase 2 studies for EDP-938 and EDP-323.
- Appointed Scott T. Rottinghaus as SVP and Chief Medical Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000095017022015505/0000950170-22-015505-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000095017022015505/enta-20220808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-015505

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer